374 related articles for article (PubMed ID: 33227561)
1. Outcomes in Retinal Vein Occlusions Presenting with Poor Visual Acuity Treated with Anti-Vascular Endothelial Growth Factor Therapy: Prognosis and Predictive Factors.
Light JG; Tian J; Wenick AS
Ophthalmol Retina; 2021 Sep; 5(9):888-900. PubMed ID: 33227561
[TBL] [Abstract][Full Text] [Related]
2. Fluctuations in Macular Thickness in Patients with Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents.
Chen AX; Greenlee TE; Conti TF; Briskin IN; Singh RP
Ophthalmol Retina; 2020 Dec; 4(12):1158-1169. PubMed ID: 32480014
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
[TBL] [Abstract][Full Text] [Related]
4. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
[TBL] [Abstract][Full Text] [Related]
5. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial.
Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; de Jong-Hesse Y; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
Ophthalmol Retina; 2020 Jun; 4(6):576-587. PubMed ID: 32107188
[TBL] [Abstract][Full Text] [Related]
6. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
[TBL] [Abstract][Full Text] [Related]
7. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice.
Khan M; Wai KM; Silva FQ; Srivastava S; Ehlers JP; Rachitskaya A; Babiuch A; Deasy R; Kaiser PK; Schachat AP; Yuan A; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2017 Jun; 48(6):465-472. PubMed ID: 28613352
[TBL] [Abstract][Full Text] [Related]
9. QUALITATIVE AND QUANTITATIVE FOLLOW-UP USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF RETINAL VEIN OCCLUSION TREATED WITH ANTI-VEGF: Optical Coherence Tomography Angiography Follow-up of Retinal Vein Occlusion.
Sellam A; Glacet-Bernard A; Coscas F; Miere A; Coscas G; Souied EH
Retina; 2017 Jun; 37(6):1176-1184. PubMed ID: 27685676
[TBL] [Abstract][Full Text] [Related]
10. Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion.
Rayess N; Rahimy E; Ying GS; Pefkianaki M; Franklin J; Regillo CD; Ho AC; Hsu J
Am J Ophthalmol; 2016 Nov; 171():47-52. PubMed ID: 27567889
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
12. Two-Year Efficacy of Ranibizumab Plus Laser-Induced Chorioretinal Anastomosis vs Ranibizumab Monotherapy for Central Retinal Vein Occlusion: A Randomized Clinical Trial.
McAllister IL; Smithies LA; Chen FK; Mackey DA; Sanfilippo PG
JAMA Ophthalmol; 2018 Dec; 136(12):1391-1397. PubMed ID: 30347030
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
[TBL] [Abstract][Full Text] [Related]
14. Visual and Anatomic Outcomes following Cataract Surgery in Patients with Pre-operative Macular Edema Due to Retinal Vein Occlusions Managed with Intravitreal anti-VEGF.
Starr MR; Mahr MA; Iezzi R; Barkmeier AJ; Bakri SJ
Semin Ophthalmol; 2020 May; 35(4):205-209. PubMed ID: 32721186
[TBL] [Abstract][Full Text] [Related]
15. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
17. SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
Ophthalmology; 2023 Oct; 130(10):1066-1072. PubMed ID: 37220815
[TBL] [Abstract][Full Text] [Related]
18. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
Hu Q; Li H; Xu W; Du Y; Ma C; He J
Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
[TBL] [Abstract][Full Text] [Related]
19. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Anatomical and Functional Outcomes in Patients with Ischemic Central Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents.
Chatziralli I; Theodossiadis G; Parikakis E; Mitropoulos PG; Theodossiadis P
Ophthalmic Res; 2017; 58(4):203-208. PubMed ID: 28427057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
